Immune checkpoint inhibition using monoclonal antibodies (mAbs) that target the cytotoxic T lymphocyte-associated protein 4 (CTLA-4) or PD-1 pathway has reshaped the landscape of therapeutic strategies for patients with CLL. Here, PDCD1 is linked to B-cell chronic lymphocytic leukemia.